ABOUT THE INFLUENCE OF INFLAMMATION IN COURSE OF ANEMIA IN HEMODIALYSIS PATIENTS

Concomitant inflammation in nephrogenic anemia is one of the most frequent complications among patients undergoing programmed hemodialysis, which can lead to the worst results of the correction of anemic syndrome. The study conducted a comparative analysis of the course of nephrogenic anemia in 31 patients with end-stage chronic kidney disease undergoing programmed hemodialysis. 2 groups were distinguished: the first group - 10 patients with laboratory signs of inflammation (C-reactive protein> 5.0 mg / l); the second group - 21 patients with no signs of inflammation (C-reactive protein <5.0 mg / L). The following laboratory parameters were evaluated: hemoglobin level, C-reactive protein, serum ferritin, gas transport function of venous blood. The quality of life of patients was assessed using the FACT questionnaire (the Functional Assessment of Cancer Therapy scale). According to the results of the study, it was found that patients with systemic inflammation have a functional iron deficiency (the median level of ferritin was 335.5 μg / l and 234.2 μg / lv in the first and second groups, respectively). In both groups, patients have similar laboratory indicators of hemoglobin level (median 98 g / l and 106 g / l in the first and second groups, respectively) and venous blood saturation (median 59.95% and 62.5%), which indicates high efficiency combination of erythro-poiesis-stimulating therapy with intravenous iron. At the same time, among patients with inflammation, a lower quality of life was observed (median scores on the FACT-An 40 and 29 scale). Concomitant inflammation in nephrogenic anemia does not affect the severity of peripheral tissue hypoxia. A statistically significant (p <0.05) inverse correlation was found between the activity of inflammatory markers (leukocytosis, C-reactive protein) and the hemoglobin level in the group of patients with inflammation.

Chronic inflammation, chronic kidney disease, anemia, hemodialysis, quality of life, venous blood saturation, erythropoiesis-stimulating therapy